Gene Therapy Poised to Tackle Debilitating Cancer Treatment Side Effect

LONDON and NEW YORK – April 14, 2026 – For many who win their battle against head and neck cancer, the victory is shadowed by a lifelong, debilitating consequence of the radiation that saved them: severe, chronic dry mouth. This Thursday, the genetic medicines company MeiraGTx will present data that could signal a turning point for these survivors, offering a glimmer of hope for a condition that has long been considered irreversible.

The company is set to unveil three-year follow-up data from its Phase 1 clinical trial of AAV-hAQP1, an investigational gene therapy for the treatment of grade 2/3 radiation-induced xerostomia (RIX). The virtual presentation on April 16th is highly anticipated by clinicians, patients, and investors, as it will provide the first long-term look at the durability and safety of this novel, one-time treatment.

The Unseen Burden of Cancer Survivorship

Radiation therapy is a cornerstone of treatment for head and neck cancers, but it is a blunt instrument. While targeting cancerous cells, the radiation often causes irreparable collateral damage to the delicate salivary glands. The result is xerostomia, a condition that affects an estimated 30-40% of the more than 650,000 head and neck cancer survivors in the United States alone.

This is far more than a simple discomfort. The constant dryness makes it difficult to speak, chew, and swallow, often leading to nutritional deficiencies and a diminished quality of life. Without the protective qualities of saliva, patients suffer from rampant tooth decay, oral infections like candidiasis, and chronic pain. Sleep is frequently disturbed by the need to sip water throughout the night.

Current treatments offer only temporary, symptomatic relief. Patients may be prescribed medications like pilocarpine to stimulate any remaining gland function, but these often come with systemic side effects like sweating and nausea. Saliva substitutes, in the form of gels and sprays, provide fleeting moisture but do not restore function. For decades, there has been no treatment that addresses the root cause of the problem—the damaged glands themselves.

A Genetic Fix for a Physical Problem

MeiraGTx's AAV-hAQP1 aims to change that paradigm by reprogramming the body's own cells. The therapy involves a simple, non-surgical procedure where a harmless adeno-associated virus (AAV) is used as a delivery vehicle. This vector is infused directly into the remaining salivary glands through the Stensen's duct in the cheek.

The AAV carries a functional copy of the human aquaporin-1 (hAQP1) gene. Aquaporins are proteins that form channels for water to pass through cell membranes. The theory is that by introducing this gene, the therapy can turn the remaining, water-impermeable ductal cells of the gland into structures that can actively transport water, effectively restoring the gland's ability to produce saliva.

This approach has already shown significant promise. The 12-month data from the Phase 1 AQUAx study, which has been publicly released, was highly encouraging. Patients treated with AAV-hAQP1 showed what MeiraGTx described as clinically meaningful improvements in their symptoms, as measured by the Xerostomia Questionnaire (XQ), a patient-reported outcome tool. More importantly, these subjective improvements were backed by objective data showing a significant increase in the Unstimulated Whole Saliva Flow Rate (UWSFR), a key measure of salivary function.

The Promise of Durability and a Pivotal Moment

While the 12-month results were a major step forward, the true test for a one-time gene therapy is durability. Will the effect last? That is the central question the upcoming three-year data is expected to answer. The presentation on Thursday will include a comprehensive look at both patient-reported symptoms and objective saliva flow measurements out to 36 months for all patients in the study, including those who received the therapy in one or both parotid glands.

MeiraGTx has announced that the presentation will include full cohort-level data as well as individual patient data, providing a granular view of the treatment's long-term effects. The company also plans to have study investigators discuss the disease burden and patient experience, lending a human perspective to the clinical data. For a field seeking to move beyond temporary fixes, proof of a lasting, multi-year benefit from a single administration would represent a monumental breakthrough.

This data release comes as the company is actively enrolling patients in AQUAx2, a randomized, double-blind, placebo-controlled Phase 2 study. Positive and durable results from the Phase 1 cohort would provide strong validation for this ongoing trial, which is designed to potentially support a future Biologics License Application (BLA) with the FDA.

Beyond Xerostomia: A Vertically Integrated Strategy

MeiraGTx's ambitions extend far beyond xerostomia. The company is advancing a broad pipeline of genetic medicines targeting diseases of the eye and central nervous system, including a late-stage program for Parkinson's disease. This diversified approach is supported by a key strategic advantage: end-to-end, in-house manufacturing.

With multiple GMP-licensed facilities, including a large-scale commercial manufacturing plant in Shannon, Ireland, MeiraGTx controls its entire production process. This vertical integration is rare in the biotech industry and allows the company to reduce costs, avoid supply chain bottlenecks, and accelerate development timelines—a critical edge in the competitive gene therapy landscape.

Strategic partnerships with pharmaceutical giants like Eli Lilly for its ophthalmology programs further bolster the company's position. This combination of a deep scientific platform, a diverse clinical pipeline, and robust manufacturing capabilities makes the upcoming data for AAV-hAQP1 not just a test of a single product, but a validation of the company's entire integrated model. The results presented this week will therefore be closely watched as a bellwether for the company's future and a potential new dawn for survivors of head and neck cancer.